The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology & Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and CT are 'world-market leaders'.
See also Bayer HealthCare Pharmaceuticals.

In June 2006 Bayer AG has bought the majority of shares of Schering AG. As a result of this take-over Schering AG has been renamed in December 2006 in Bayer Schering Pharma AG. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
Berlex Laboratories (USA) and Berlex Canada Inc., former affiliates of Schering AG, have been integrated into Bayer HealthCare and operate as a specialty pharmaceuticals business that also sells MRI contrast agents, under the name Bayer HealthCare Pharmaceuticals, which is a subsidiary of Bayer Schering Pharma AG.

The company is developing and making specialized medicines for treating multiple sclerosis, dermatological disorders, female health concerns, cancer and is creating new diagnostic imaging techniques. Berlex, Inc. is a pioneer in the imaging market. It has introduced a broad range of imaging agents. Its contribution began in 1988 with the introduction of the world's first magnetic resonance imaging agent, Magnevist® (gadopentetate dimeglumine) injection. Berlex is headquartered in New Jersey and the U.S. affiliate of Bayer Schering Pharma AG, Germany.

Biliscopin® Infusion, an iodinated contrast medium for intravenous cholecystography is secreted actively by the hepatocytes. The biliary excretion rate of a biliary contrast medium is determined by the binding to plasma proteins and liver receptor proteins, and by its transport maximum for the liver. Because of its high hepatocellular transport rate, Biliscopin® Infusion leads rapidly to high grade contrast density in the intra-hepatic and extra-hepatic biliary ducts as well as in the gallbladder.
Computed tomography with biliary contrast agents provides maximum quality preoperative imaging of the biliary tract.

Isovist® is a nonionic x-ray contrast agent. Isovist® is suitable for intrathecal applications for example CT myelography, cisternography, the evaluation of cerebrospinal fluid (CSF) circulation and for use in other body cavities. Opacification is directly visible after administration of Iotrolan to the spinal subarachnoid space and various open body cavities. Isovist® flows with the CSF through the arachnoid villi into the venous blood.